CIK 1940272
ADAR1 Capital Management, LLC
Institutional 13F holdings & portfolio
Holdings
512
Portfolio Value
$1M+
Latest Report
Dec 31, 2025
Report Periods
1
Holdings
13F filings as of Dec 31, 2025 · Showing 451–500 of 512
| Ticker | Company | Shares | Value | Type |
|---|---|---|---|---|
| QNCX | QUINCE THERAPEUTICS INC | 43K | $100K–$500K | SH |
| QNCX | QUINCE THERAPEUTICS INC | 43K | $100K–$500K | SH |
| SLN | SILENCE THERAPEUTICS PLC | 24K | $100K–$500K | SH |
| SLN | SILENCE THERAPEUTICS PLC | 24K | $100K–$500K | SH |
| RXRX | RECURSION PHARMACEUTICALS IN | 35K | $100K–$500K | SH |
| RXRX | RECURSION PHARMACEUTICALS IN | 35K | $100K–$500K | SH |
| VYGR | VOYAGER THERAPEUTICS INC | 35K | $100K–$500K | SH |
| VYGR | VOYAGER THERAPEUTICS INC | 35K | $100K–$500K | SH |
| ZONE | CLEANCORE SOLUTIONS INC | 522K | $100K–$500K | SH |
| ZONE | CLEANCORE SOLUTIONS INC | 522K | $100K–$500K | SH |
| CMMB | CHEMOMAB THERAPEUTICS LTD | 80K | $100K–$500K | SH |
| CMMB | CHEMOMAB THERAPEUTICS LTD | 80K | $100K–$500K | SH |
| PMVP | PMV PHARMACEUTICALS INC | 101K | $100K–$500K | SH |
| PMVP | PMV PHARMACEUTICALS INC | 101K | $100K–$500K | SH |
| GBIO | GENERATION BIO CO | 22K | $100K–$500K | SH |
| GBIO | GENERATION BIO CO | 22K | $100K–$500K | SH |
| NEUP | NEUPHORIA THERAPEUTICS INC | 30K | $100K–$500K | SH |
| NEUP | NEUPHORIA THERAPEUTICS INC | 30K | $100K–$500K | SH |
| CLOV | CLOVER HEALTH INVESTMENTS CO | 48K | $100K–$500K | SH |
| CLOV | CLOVER HEALTH INVESTMENTS CO | 48K | $100K–$500K | SH |
| ZNTL | ZENTALIS PHARMACEUTICALS INC | 80K | $100K–$500K | SH |
| ZNTL | ZENTALIS PHARMACEUTICALS INC | 80K | $100K–$500K | SH |
| BCAB | BIOATLA INC | 183K | $100K–$500K | SH |
| BCAB | BIOATLA INC | 183K | $100K–$500K | SH |
| SABS | SAB BIOTHERAPEUTICS INC | 26K | $50K–$100K | SH |
| SABS | SAB BIOTHERAPEUTICS INC | 26K | $50K–$100K | SH |
| STI | SOLIDION TECHNOLOGY INC | 14K | $50K–$100K | SH (Call) |
| STI | SOLIDION TECHNOLOGY INC | 14K | $50K–$100K | SH (Call) |
| KYNB | FIBROGEN INC | 10K | $50K–$100K | SH |
| KYNB | FIBROGEN INC | 10K | $50K–$100K | SH |
| RZLT | REZOLUTE INC | 39K | $50K–$100K | SH |
| RZLT | REZOLUTE INC | 39K | $50K–$100K | SH |
| NMRA | NEUMORA THERAPEUTICS INC. | 51K | $50K–$100K | SH |
| NMRA | NEUMORA THERAPEUTICS INC. | 51K | $50K–$100K | SH |
| PLRX | PLIANT THERAPEUTICS INC | 74K | $50K–$100K | SH |
| PLRX | PLIANT THERAPEUTICS INC | 74K | $50K–$100K | SH |
| LITS | LITE STRATEGY INC | 67K | $50K–$100K | SH |
| LITS | LITE STRATEGY INC | 67K | $50K–$100K | SH |
| IRD | OPUS GENETICS INC | 40K | $50K–$100K | SH |
| IRD | OPUS GENETICS INC | 40K | $50K–$100K | SH |
| KALA | KALA BIO INC | 141K | $50K–$100K | SH |
| KALA | KALA BIO INC | 141K | $50K–$100K | SH |
| VERU | VERU INC | 35K | $50K–$100K | SH |
| VERU | VERU INC | 35K | $50K–$100K | SH |
| QTTB | Q32 BIO INC | 20K | $50K–$100K | SH |
| QTTB | Q32 BIO INC | 20K | $50K–$100K | SH |
| MREO | MEREO BIOPHARMA GROUP PLC | 150K | $50K–$100K | SH |
| MREO | MEREO BIOPHARMA GROUP PLC | 150K | $50K–$100K | SH |
| BMEA | BIOMEA FUSION INC | 43K | $50K–$100K | SH |
| BMEA | BIOMEA FUSION INC | 43K | $50K–$100K | SH |